Smallpox

MedMira enters collaboration for smallpox vaccine antibody detection test

Published in Vaccine Weekly, January 8th, 2003

MedMira, Inc., (MIR) announced that it has reached a collaboration venture with a Canadian biopharmaceutical company, Cangene Corp. (CNJ), which will facilitate MedMira in reaching the global market for detection of the protective antibodies against smallpox following vaccination.

The smallpox vaccine consists of a live vaccinia virus which produces an immune defense to smallpox infection in humans. The traditional method for determining the success of vaccination against smallpox was a subjective observation of the presence of a lesion or scar by a healthcare professional.

The gold standard laboratory test, the plaque reduction neutralization test...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2003-01-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry